Compare APRE & CVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APRE | CVR |
|---|---|---|
| Founded | 2006 | 1920 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.4M |
| IPO Year | 2019 | 1995 |
| Metric | APRE | CVR |
|---|---|---|
| Price | $0.88 | $11.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 448.0K | 2.7K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | ★ 21.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,890,260.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.35 |
| 52 Week Low | $0.55 | $8.15 |
| 52 Week High | $2.22 | $15.00 |
| Indicator | APRE | CVR |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 52.12 |
| Support Level | $0.90 | $11.13 |
| Resistance Level | $0.98 | $14.51 |
| Average True Range (ATR) | 0.10 | 0.39 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 56.18 | 81.64 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.